Logo image of 1JNJ.MI

JOHNSON & JOHNSON (1JNJ.MI) Stock Fundamental Analysis

Europe - Euronext Milan - BIT:1JNJ - US4781601046 - Common Stock

182.02 EUR
+7.9 (+4.54%)
Last: 12/15/2025, 7:00:00 PM
Fundamental Rating

5

Overall 1JNJ gets a fundamental rating of 5 out of 10. We evaluated 1JNJ against 54 industry peers in the Pharmaceuticals industry. 1JNJ has an excellent profitability rating, but there are some minor concerns on its financial health. 1JNJ is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year 1JNJ was profitable.
In the past year 1JNJ had a positive cash flow from operations.
Each year in the past 5 years 1JNJ has been profitable.
1JNJ had a positive operating cash flow in each of the past 5 years.
1JNJ.MI Yearly Net Income VS EBIT VS OCF VS FCF1JNJ.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

1.2 Ratios

With an excellent Return On Assets value of 13.03%, 1JNJ belongs to the best of the industry, outperforming 81.48% of the companies in the same industry.
1JNJ has a Return On Equity of 31.69%. This is in the better half of the industry: 1JNJ outperforms 75.93% of its industry peers.
The Return On Invested Capital of 1JNJ (14.68%) is better than 74.07% of its industry peers.
1JNJ had an Average Return On Invested Capital over the past 3 years of 15.41%. This is in line with the industry average of 13.79%.
Industry RankSector Rank
ROA 13.03%
ROE 31.69%
ROIC 14.68%
ROA(3y)12.79%
ROA(5y)11.65%
ROE(3y)31.38%
ROE(5y)29.12%
ROIC(3y)15.41%
ROIC(5y)14.48%
1JNJ.MI Yearly ROA, ROE, ROIC1JNJ.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

With an excellent Profit Margin value of 27.26%, 1JNJ belongs to the best of the industry, outperforming 87.04% of the companies in the same industry.
In the last couple of years the Profit Margin of 1JNJ has declined.
1JNJ's Operating Margin of 27.00% is fine compared to the rest of the industry. 1JNJ outperforms 74.07% of its industry peers.
In the last couple of years the Operating Margin of 1JNJ has grown nicely.
With a Gross Margin value of 68.14%, 1JNJ perfoms like the industry average, outperforming 48.15% of the companies in the same industry.
1JNJ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27%
PM (TTM) 27.26%
GM 68.14%
OM growth 3Y0.33%
OM growth 5Y3.14%
PM growth 3Y-15.79%
PM growth 5Y-2.98%
GM growth 3Y-0.56%
GM growth 5Y0.76%
1JNJ.MI Yearly Profit, Operating, Gross Margins1JNJ.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1JNJ is still creating some value.
Compared to 1 year ago, 1JNJ has about the same amount of shares outstanding.
The number of shares outstanding for 1JNJ has been reduced compared to 5 years ago.
1JNJ has a worse debt/assets ratio than last year.
1JNJ.MI Yearly Shares Outstanding1JNJ.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B
1JNJ.MI Yearly Total Debt VS Total Assets1JNJ.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

1JNJ has an Altman-Z score of 4.86. This indicates that 1JNJ is financially healthy and has little risk of bankruptcy at the moment.
1JNJ has a Altman-Z score of 4.86. This is in the better half of the industry: 1JNJ outperforms 74.07% of its industry peers.
The Debt to FCF ratio of 1JNJ is 2.34, which is a good value as it means it would take 1JNJ, 2.34 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 2.34, 1JNJ is doing good in the industry, outperforming 75.93% of the companies in the same industry.
1JNJ has a Debt/Equity ratio of 0.55. This is a neutral value indicating 1JNJ is somewhat dependend on debt financing.
1JNJ has a Debt to Equity ratio of 0.55. This is comparable to the rest of the industry: 1JNJ outperforms 50.00% of its industry peers.
Although 1JNJ does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.34
Altman-Z 4.86
ROIC/WACC1.5
WACC9.77%
1JNJ.MI Yearly LT Debt VS Equity VS FCF1JNJ.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.3 Liquidity

A Current Ratio of 1.07 indicates that 1JNJ should not have too much problems paying its short term obligations.
1JNJ's Current ratio of 1.07 is on the low side compared to the rest of the industry. 1JNJ is outperformed by 72.22% of its industry peers.
A Quick Ratio of 0.80 indicates that 1JNJ may have some problems paying its short term obligations.
With a Quick ratio value of 0.80, 1JNJ is not doing good in the industry: 64.81% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 0.8
1JNJ.MI Yearly Current Assets VS Current Liabilites1JNJ.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.37% over the past year.
The Earnings Per Share has been growing slightly by 2.85% on average over the past years.
Looking at the last year, 1JNJ shows a small growth in Revenue. The Revenue has grown by 5.08% in the last year.
The Revenue has been growing slightly by 1.60% on average over the past years.
EPS 1Y (TTM)1.37%
EPS 3Y0.64%
EPS 5Y2.85%
EPS Q2Q%15.7%
Revenue 1Y (TTM)5.08%
Revenue growth 3Y4.1%
Revenue growth 5Y1.6%
Sales Q2Q%6.77%

3.2 Future

1JNJ is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.68% yearly.
1JNJ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.29% yearly.
EPS Next Y9.85%
EPS Next 2Y8.02%
EPS Next 3Y7.82%
EPS Next 5Y7.68%
Revenue Next Year5.61%
Revenue Next 2Y5.47%
Revenue Next 3Y5.32%
Revenue Next 5Y5.29%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
1JNJ.MI Yearly Revenue VS Estimates1JNJ.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B 100B
1JNJ.MI Yearly EPS VS Estimates1JNJ.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

3

4. Valuation

4.1 Price/Earnings Ratio

1JNJ is valuated rather expensively with a Price/Earnings ratio of 20.59.
1JNJ's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.50, 1JNJ is valued a bit cheaper.
A Price/Forward Earnings ratio of 18.34 indicates a rather expensive valuation of 1JNJ.
1JNJ's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 23.93. 1JNJ is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 20.59
Fwd PE 18.34
1JNJ.MI Price Earnings VS Forward Price Earnings1JNJ.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

1JNJ's Enterprise Value to EBITDA ratio is in line with the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as 1JNJ.
Industry RankSector Rank
P/FCF 26.28
EV/EBITDA 16.36
1JNJ.MI Per share data1JNJ.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of 1JNJ may justify a higher PE ratio.
PEG (NY)2.09
PEG (5Y)7.22
EPS Next 2Y8.02%
EPS Next 3Y7.82%

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 2.47%, 1JNJ has a reasonable but not impressive dividend return.
1JNJ's Dividend Yield is a higher than the industry average which is at 1.85.
Compared to an average S&P500 Dividend Yield of 1.87, 1JNJ pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 2.47%

5.2 History

The dividend of 1JNJ is nicely growing with an annual growth rate of 9.24%!
Dividend Growth(5Y)9.24%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

1JNJ pays out 48.70% of its income as dividend. This is a bit on the high side, but may be sustainable.
1JNJ's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP48.7%
EPS Next 2Y8.02%
EPS Next 3Y7.82%
1JNJ.MI Yearly Income VS Free CF VS Dividend1JNJ.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B
1JNJ.MI Dividend Payout.1JNJ.MI Dividend Payout, showing the Payout Ratio.1JNJ.MI Dividend Payout.PayoutRetained Earnings

JOHNSON & JOHNSON

BIT:1JNJ (12/15/2025, 7:00:00 PM)

182.02

+7.9 (+4.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-14 2025-10-14/bmo
Earnings (Next)01-21 2026-01-21/amc
Inst Owners74.99%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap438.54B
Revenue(TTM)92.15B
Net Income(TTM)25.12B
Analysts75.63
Price Target183.68 (0.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.47%
Yearly Dividend4.19
Dividend Growth(5Y)9.24%
DP48.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.42%
Min EPS beat(2)0.55%
Max EPS beat(2)2.3%
EPS beat(4)4
Avg EPS beat(4)2.37%
Min EPS beat(4)0.55%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.79%
EPS beat(12)11
Avg EPS beat(12)3.6%
EPS beat(16)14
Avg EPS beat(16)3.08%
Revenue beat(2)2
Avg Revenue beat(2)1.48%
Min Revenue beat(2)0.03%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)0.74%
Min Revenue beat(4)-0.55%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.34%
Revenue beat(12)7
Avg Revenue beat(12)-2.01%
Revenue beat(16)7
Avg Revenue beat(16)-8.34%
PT rev (1m)4.15%
PT rev (3m)18.74%
EPS NQ rev (1m)0.12%
EPS NQ rev (3m)-1.73%
EPS NY rev (1m)0%
EPS NY rev (3m)0.05%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)0.39%
Valuation
Industry RankSector Rank
PE 20.59
Fwd PE 18.34
P/S 5.59
P/FCF 26.28
P/OCF 21.28
P/B 6.5
P/tB N/A
EV/EBITDA 16.36
EPS(TTM)8.84
EY4.86%
EPS(NY)9.93
Fwd EY5.45%
FCF(TTM)6.93
FCFY3.8%
OCF(TTM)8.55
OCFY4.7%
SpS32.56
BVpS28.02
TBVpS-6.19
PEG (NY)2.09
PEG (5Y)7.22
Graham Number74.65
Profitability
Industry RankSector Rank
ROA 13.03%
ROE 31.69%
ROCE 17.53%
ROIC 14.68%
ROICexc 16.82%
ROICexgc 69.32%
OM 27%
PM (TTM) 27.26%
GM 68.14%
FCFM 21.27%
ROA(3y)12.79%
ROA(5y)11.65%
ROE(3y)31.38%
ROE(5y)29.12%
ROIC(3y)15.41%
ROIC(5y)14.48%
ROICexc(3y)18.76%
ROICexc(5y)17.88%
ROICexgc(3y)74.12%
ROICexgc(5y)78.04%
ROCE(3y)18.6%
ROCE(5y)17.28%
ROICexgc growth 3Y1.2%
ROICexgc growth 5Y-0.66%
ROICexc growth 3Y3.58%
ROICexc growth 5Y3.41%
OM growth 3Y0.33%
OM growth 5Y3.14%
PM growth 3Y-15.79%
PM growth 5Y-2.98%
GM growth 3Y-0.56%
GM growth 5Y0.76%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.34
Debt/EBITDA 1.36
Cap/Depr 62.36%
Cap/Sales 5%
Interest Coverage 250
Cash Conversion 75.02%
Profit Quality 78.02%
Current Ratio 1.07
Quick Ratio 0.8
Altman-Z 4.86
F-Score5
WACC9.77%
ROIC/WACC1.5
Cap/Depr(3y)59.5%
Cap/Depr(5y)54.84%
Cap/Sales(3y)5.11%
Cap/Sales(5y)4.8%
Profit Quality(3y)96.25%
Profit Quality(5y)104.12%
High Growth Momentum
Growth
EPS 1Y (TTM)1.37%
EPS 3Y0.64%
EPS 5Y2.85%
EPS Q2Q%15.7%
EPS Next Y9.85%
EPS Next 2Y8.02%
EPS Next 3Y7.82%
EPS Next 5Y7.68%
Revenue 1Y (TTM)5.08%
Revenue growth 3Y4.1%
Revenue growth 5Y1.6%
Sales Q2Q%6.77%
Revenue Next Year5.61%
Revenue Next 2Y5.47%
Revenue Next 3Y5.32%
Revenue Next 5Y5.29%
EBIT growth 1Y2.89%
EBIT growth 3Y4.44%
EBIT growth 5Y4.79%
EBIT Next Year30.64%
EBIT Next 3Y13.37%
EBIT Next 5Y8.85%
FCF growth 1Y24.53%
FCF growth 3Y0.14%
FCF growth 5Y-0.08%
OCF growth 1Y19.36%
OCF growth 3Y1.2%
OCF growth 5Y0.72%

JOHNSON & JOHNSON / 1JNJ.MI FAQ

What is the fundamental rating for 1JNJ stock?

ChartMill assigns a fundamental rating of 5 / 10 to 1JNJ.MI.


Can you provide the valuation status for JOHNSON & JOHNSON?

ChartMill assigns a valuation rating of 3 / 10 to JOHNSON & JOHNSON (1JNJ.MI). This can be considered as Overvalued.


What is the profitability of 1JNJ stock?

JOHNSON & JOHNSON (1JNJ.MI) has a profitability rating of 7 / 10.


What is the earnings growth outlook for JOHNSON & JOHNSON?

The Earnings per Share (EPS) of JOHNSON & JOHNSON (1JNJ.MI) is expected to grow by 9.85% in the next year.


Can you provide the dividend sustainability for 1JNJ stock?

The dividend rating of JOHNSON & JOHNSON (1JNJ.MI) is 5 / 10 and the dividend payout ratio is 48.7%.